Sun Pharma commences Tender Offer for acquisition of InSite Vision

30 Sep 2015 Evaluate

Sun Pharmaceutical Industries has commenced a tender offer through its indirect wholly owned subsidiary, Thea Acquisition Corporation, for all of the outstanding shares of common stock (the ‘Shares’) of InSite Vision Incorporated for $0.35 per share in cash, without interest and less any required withholding taxes.

The tender offer is being made pursuant to an Offer to Purchase, dated September 29, 2015, and in connection with the previously announced Agreement and Plan of Merger, dated September 15, 2015, as amended and restated as of September 28, 2015, by and among InSite Vision, Ranbaxy, Inc. and Thea Acquisition Corporation.

The tender offer will expire on October 27, 2015, at 12:00 midnight New York City time (the end of the day), unless extended in accordance with the Merger Agreement and the applicable rules and regulations of the Securities and Exchange Commission. Any extension of the tender offer will be followed as promptly as practicable by public announcement thereof, and such announcement will be made no later than 9:00 a.m. New York City time on the next business day after the previously scheduled expiration date.

The tender offer is subject to customary conditions, induding the tender of a majority of the outstanding Shares (calculated on a fully-diluted basis). InSite Vision's board of directors has also approved the transaction and unanimously recommended that its stockholders tender their shares pursuant to the tender offer.

Sun Pharma Inds. Share Price

1725.15 4.75 (0.28%)
02-Jan-2026 09:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.15
Dr. Reddys Lab 1240.75
Cipla 1504.10
Zydus Lifesciences 914.95
Lupin 2104.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×